Gurnee, IL, United States of America

Jerry A Hall

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 31(Granted Patents)


Location History:

  • Cleveland, TN (US) (1992)
  • Gurnee, IL (2013)
  • Gurnee, IL (US) (2016)

Company Filing History:


Years Active: 1992-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jerry A Hall: Innovator in Antibody Development

Introduction

Jerry A Hall is a notable inventor based in Gurnee, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 3 patents to his name, Hall's work focuses on enhancing the stability and efficacy of therapeutic antibodies.

Latest Patents

One of Hall's latest patents is centered around antibodies against nerve growth factor (NGF) with enhanced in vivo stability. This invention provides anti-NGF antibodies that contain an IgG4 constant region with a stabilizing hinge region mutation. The antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Additionally, the patent includes pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies, and methods for using these antibodies to treat NGF-related diseases or conditions.

Career Highlights

Throughout his career, Jerry A Hall has worked with prominent organizations, including Abbott Research B.V. His innovative work has positioned him as a key figure in the biotechnology sector, contributing to advancements in therapeutic treatments.

Collaborations

Hall has collaborated with notable colleagues such as John Powell and Duncan Casson. These partnerships have further enriched his research and development efforts in the field of antibody technology.

Conclusion

Jerry A Hall's contributions to the development of stable anti-NGF antibodies highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options in treating nerve growth factor-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…